(Q24242948)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425951%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

0 references

1 reference

title

Paliperidone for schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425951%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425951%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

T. Scott Stroup

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425951%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Abraham M Nussbaum

series ordinal

1

0 references

T S Stroup

series ordinal

2

0 references

publication date

16 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425951%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425951%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425951%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

CD006369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425951%20AND%20SRC:MED&resulttype=core&format=json

Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Antipsychotic-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

21 January 2018

Paliperidone: quo vadis?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Study of the complexation of risperidone and 9-hydroxyrisperidone with cyclodextrin hosts using affinity capillary electrophoresis and (1)H NMR spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone: a new extended-release oral atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone: An improvement over risperidone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Prolactin and dopamine: what is the connection? A review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Secondary delusional parasitosis treated with paliperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Risperidone versus other atypical antipsychotic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Onset and persistence of antipsychotic response in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Depot risperidone for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Risperidone versus typical antipsychotic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

21 January 2018

New drug update: 2007.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Choreatic symptoms during and after treatment with paliperidone and escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Transfer of risperidone and 9-hydroxyrisperidone into human milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Risperidone versus olanzapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

What are the nursing implications when using paliperidone prolonged release for people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone-ER: first atypical antipsychotic with oral extended release formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone extended-release for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone in an adult patient with Asperger syndrome: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Apparent seizure and atrial fibrillation associated with paliperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Paliperidone extended release

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

1 reference

7 January 2021

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

Self-report quality of life measure for people with schizophrenia: the SQLS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006369.PUB2

7 January 2021

10.1002/14651858.CD006369.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425951%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017